Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Net Margin (2016 - 2025)

Historic Net Margin for Harvard Bioscience (HBIO) over the last 16 years, with Q3 2025 value amounting to 5.99%.

  • Harvard Bioscience's Net Margin rose 158600.0% to 5.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 61.53%, marking a year-over-year decrease of 470100.0%. This contributed to the annual value of 13.18% for FY2024, which is 101400.0% down from last year.
  • Latest data reveals that Harvard Bioscience reported Net Margin of 5.99% as of Q3 2025, which was up 158600.0% from 11.17% recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Net Margin peaked at 8.34% during Q2 2022, and registered a low of 230.98% during Q1 2025.
  • In the last 5 years, Harvard Bioscience's Net Margin had a median value of 5.99% in 2025 and averaged 18.56%.
  • Its Net Margin has fluctuated over the past 5 years, first surged by 259300bps in 2023, then tumbled by -2118300bps in 2025.
  • Harvard Bioscience's Net Margin (Quarter) stood at 1.78% in 2021, then tumbled by -526bps to 7.61% in 2022, then grew by 15bps to 6.46% in 2023, then surged by 103bps to 0.2% in 2024, then tumbled by -3043bps to 5.99% in 2025.
  • Its Net Margin was 5.99% in Q3 2025, compared to 11.17% in Q2 2025 and 230.98% in Q1 2025.